Even someone as optimistic as I am could not have predicted the global impact DrugDev would have on pharma in 2017. It'is a tribute to our technology and our expert service professionals that so many customers use our technology platform to fundamentally change the economics of clinical trials.
PHILADELPHIA and LONDON (PRWEB) February 05, 2018
DrugDev achieved tremendous growth in 2017 as pharma and biotech organizations of all sizes worldwide adopted its strategy to advance clinical trials through industry-wide collaboration, standardization and a beautiful technology experience.
The company more than doubled new business orders as adoption of the DrugDev Spark™ clinical operations suite continues to steadily climb to over 100 pharmaceutical and biotechnology customers. On top of this success, several of the world’s leading global drug development companies committed to improving the site, patient and study team experience for their clinical trials by implementing DrugDev Spark enterprise wide across thousands of global trials. The organic growth and enterprise success together resulted in the staggering growth over what was a prosperous 2016.
DrugDev President and CEO Ibs Mahmood said, “Even someone as optimistic as I am could not have predicted the global impact DrugDev would have on the pharma industry in 2017. It is a tribute to our technology and our expert service professionals that so many customers are using our technology platform to fundamentally change the economics of clinical trials and bring more beneficial treatments that have the potential to improve the lives of millions of patients worldwide. This is happening on individual trials at companies of all sizes, and globally across the world’s largest organizations. I could not be more excited about the opportunity we have in front of us to change how clinical trials are run.”
2017 marked a banner year due to achievements such as DrugDev deploying patient consent on its 100th clinical trial, expanding its adoption in Europe, and reaching a historic milestone of $2 billion in site payments processed. Perhaps most importantly, DrugDev was acquired to grow the core of IQVIA (then QuintilesIMS)’s clinical technology solutions.
DrugDev also contributed thought leadership throughout 2017, highlighted by hosting its annual Summit which was co-chaired by Novartis and CSL Behring in Philadelphia. More than 125 innovative leaders from 50 sponsors and sites of all sizes met to share best practices, concerns and ideas for advancing the adoption of DrugDev and related technologies to transform how global clinical trials are run. Customer case studies and presentations included centralizing global operations, enterprise-wide technology deployments, improved patient enrollment, faster site activation, eConsent site adoption strategies, and evidence-based site selection tactics.
In addition, DrugDev customers and partners participated in a series of educational webinars that encouraged important conversations. Topics included a Novartis case study on using eConsent on a global basis, a Society of Clinical Research Sites (SCRS) webinar on why outsourcing site payments makes sense, overcoming challenge of rare disease trials with Alnylam, and cross-functional strategies for site startup planning. DrugDev executives and subject matter experts were likewise featured speakers at conferences including the SCOPE Summit, Partnerships in Clinical Trials Europe, ACRP Meeting & Expo, the Clinical Leader Forum, MAGI, Proventa Europe, and Linking Leaders.
To round out 2017, the company’s technology and leadership were honored to receive distinguished industry awards including…
The DrugDev Golden Number – this groundbreaking source of the truth for clinical trials won the coveted Clinical Informatics News 2017 Best Practices Award for improving clinical trial startup and data management. Over one-third of all global clinical trials sponsored by industry are indexed to the DrugDev Golden Number, the industry-standard identifier for clinical site facilities and staff.
DrugDev President, Patient Consent Eric Delente in the PharmaVOICE 100 – Delente, the visionary technologist largely responsible for commercializing eConsent, was named one of the PharmaVOICE 100 most influential and inspiring people in life.
DrugDev Chief Product Officer Elisa Cascade – The Medicine Maker POWER 100 voted Cascade one of the 100 most influential people in life sciences for her ability to champion meaningful change in the way pharma uses data to improve clinical trials. Additionally, Cascade was elected to the ACRP Board of Trustees, where she is fostering the organization’s mission to drive excellence in the conduct of clinical research.
“Looking back now, it’s incredible how much we accomplished with our customers in 2017,” added Ibs Mahmood. “We could not be more excited or fortunate to work with so many innovative leaders in the industry who are determined to change the status quo. I’m confident 2017, despite its success, will be merely a springboard to bigger and better things as we head into 2018 as a key part of IQVIA’s clinical technology strategy.”
DrugDev, an IQVIA company, helps the world do more trials through industry-wide collaboration, standardization and a beautiful technology experience. DrugDev Spark™, the unified clinical operations suite, is comprised of proven solutions used by over 100 sponsors and CROs on over 2,000 clinical trials to transform the quality and efficiency of clinical trials from startup through closeout. DrugDev Spark is powered by the DrugDev Golden Number, the award-winning universal identifier for global site facilities and investigators used by TransCelerate and the Investigator Databank. Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs trust DrugDev by scheduling a demo of DrugDev Spark at drugdev.com.